Art. -Nr.: HY-N0643

Carnosol

17 Cited Publications

Kundenbewertung

Based on 17 publication(s) in Google Scholar

Carnosol is a potent Ribosomal S6 Kinase (RSK2) inhibitor that could be useful for treating gastric cancer, with an IC₅₀ of ~5.5 μM. Carnosol, a Nrf2 activator, increases the nuclear levels of Nrf2 and can promote the expression of heme oxygenase 1 (HMOX1).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.79%
CAS. Nr.: 5957-80-2
Formel: C₂₀H₂₆O₄
Molecular Weight:330.42

Speicherung:

Powder -20°C, 3 years

* The compound is unstable in solutions, freshly prepared is recommended.

Carnosol Chemical Structure

CAS. Nr.: 5957-80-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (17)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Carnosol is a potent Ribosomal S6 Kinase (RSK2) inhibitor that could be useful for treating gastric cancer, with an IC₅₀ of ~5.5 μM^[1]. Carnosol, a Nrf2 activator, increases the nuclear levels of Nrf2 and can promote the expression of heme oxygenase 1 (HMOX1)^[2]^[3].

IC₅₀ & Target^[1]^[2]

RSK2

~5.5 μM (IC₅₀)

Nrf2

Alle Ribosomal S6 Kinase (RSK) Isoform-spezifische Produkte anzeigen :

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	GI₅₀	3.6 μM Compound: 2	Cytotoxicity against human A2780 cells after 48 hrs by SRB assay Cytotoxicity against human A2780 cells after 48 hrs by SRB assay	[PMID: 17190465]
A549	IC₅₀	>60 μM Compound: 1	Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
A549	IC₅₀	47 μM Compound: 1	Cytotoxicity against human A549 cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
A549	IC₅₀	5 μM Compound: 7	Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	10.1039/C5MD00278H
HBL-100	GI₅₀	3.9 μM Compound: 2	Cytotoxicity against human HBL100 cells after 48 hrs by SRB assay Cytotoxicity against human HBL100 cells after 48 hrs by SRB assay	[PMID: 17190465]
HeLa	IC₅₀	>60 μM Compound: 1	Cytotoxicity against human HeLa cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human HeLa cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
HeLa	IC₅₀	43.9 μM Compound: 1	Cytotoxicity against human HeLa cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human HeLa cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
MCF7	IC₅₀	40.9 μM Compound: 1	Cytotoxicity against human MCF7 cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
MCF7	IC₅₀	44.5 μM Compound: 1	Cytotoxicity against human sMCF7 cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against human sMCF7 cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
SW1573	GI₅₀	10 μM Compound: 2	Cytotoxicity against human SW1573 cells after 48 hrs by SRB assay Cytotoxicity against human SW1573 cells after 48 hrs by SRB assay	[PMID: 17190465]
T47D	GI₅₀	24 μM Compound: 2	Cytotoxicity against human T47D cells after 48 hrs by SRB assay Cytotoxicity against human T47D cells after 48 hrs by SRB assay	[PMID: 17190465]
Vero	IC₅₀	>60 μM Compound: 1	Cytotoxicity against african green monkey Vero cells at lag phase of growth after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells at lag phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
Vero	IC₅₀	51.5 μM Compound: 1	Cytotoxicity against african green monkey Vero cells at exponential phase of growth after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells at exponential phase of growth after 48 hrs by MTT assay	[PMID: 19711987]
WiDr	GI₅₀	26 μM Compound: 2	Cytotoxicity against human WiDr cells after 48 hrs by SRB assay Cytotoxicity against human WiDr cells after 48 hrs by SRB assay	[PMID: 17190465]

In Vitro

It is showed that carnosol has no cytotoxic effects on GES1 cells and 10 μM carnosol strongly suppresses RSK2 activity, but has little effect on any other kinase. Carnosol exerts strong dose-dependent inhibitory effects against RSK2 autophosphorylation and phosphorylation of its substrate ATF1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Results indicate that Carnosol significantly decreaseS the volume and weight of gastric tumors relative to the vehicle-treated group. Additionally, mice tolerate treatment with carnosol without significant loss of body weight similar to the vehicle-treated group. The phosphorylation of CREB, a direct downstream protein of RSK2, Is strongly inhibited in the carnosol-treated group but the expression of total CREB is relatively unchanged^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 5957-80-2
Appearance Solid
Molecular Weight 330.42
Formel C₂₀H₂₆O₄
Color White to off-white
SMILES

O=C1O[C@]2([H])C3=C(C(O)=C(O)C(C(C)C)=C3)[C@@]41CCCC(C)(C)[C@]4([H])C2
Structure Classification
- Terpenoids
- Diterpenoids
- Phenols
- Polyphenols
Initial Source
- Plants
- Labiatae
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (17)

All In Vivo Efficacy StudyWBCell Imaging/Staining

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Multi-Targeting Carnosic Acid Kills Drug-Resistant Helicobacter pylori With Narrow-Spectrum Activity. [Abstract]

2026 Jun 11:e76080. PMID: 42272345
Int J Surg

Distinct roles of HMOX1 on tumor epithelium and macrophage for regulation of immune microenvironment in ovarian cancer. [Abstract]

2025 Jul 9. PMID: 40638251

Carnosol purchased from MedChemExpress. Usage Cited in: Int J Surg. 2025 Jul 9. [Abstract]

Carnosol (200 mg/kg i.p. injection every 3 days). Combined application of CytoTRACE to dissect HMOX1_malignant+ and HMOX1_malignant− cells. (E) Tumor growth in ID8 tumor-bearing mice treated with saline, IgG, αPD-1, carnosol or αPD-1 + carnosol (n = 8 mice/group). Tumor growth was monitored by measuring the tumor volume for 2 weeks.

Carnosol purchased from MedChemExpress. Usage Cited in: Int J Surg. 2025 Jul 9. [Abstract]

Carnosol (200 mg/kg i.p. injection every 3 days). Tumor growth in mice bearing ID8, Mice were given saline, IgG, αPD-1, carnosol, IMD0354, carnosol + αPD-1, IMD0354 + αPD-1 or carnosol + IMD0354 + αPD-1. N = 8 mice/group. Tumor growth was monitored by measuring the tumor volume for 2 weeks.
Cell Death Dis

The interaction between STING and NCOA4 exacerbates lethal sepsis by orchestrating ferroptosis and inflammatory responses in macrophages. [Abstract]

2022 Jul 28;13(7):653. PMID: 35902564

Carnosol purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Jul 28;13(7):653. [Abstract]

Survival analysis of the indicated mice in CLP-induced sepsis with or without treatment of 10 mg/kg HET0016, 20 mg/kg JSH-23, or 10 mg/kg Carnosol at 2 h before CLP and 12, 24, 48, and 72 h after CLP (n = 15 per group).
Biomed Pharmacother

Advances in identifying functional groups in carnosol analogues to address their efficacy in skeletal muscle function. [Abstract]

2025 Sep:190:118397. PMID: 40753935

Carnosol purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2025 Sep:190:118397. [Abstract]

Minced gastrocnemius muscles from six-month-old C57BL/6 male mice were mixed with ethanol (0.01 %; solvent; CTRL), BHT (positive control), carnosol (CO), rosmanol (ROS), isoromanol (ISOR), dimethylcarnosol (DCO) or dimethylisorosmanol (DISOR), all dissolved in ethanol and mixed at 0.01 % w/w minced muscle. At day 0 and day 7 of refrigerated storage (+4 °C), lipid oxidation was evaluated by TBARS quantification.

Carnosol purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2025 Sep:190:118397. [Abstract]

Carnosol (CO, 48 h at 10 μM). Human myotubes treated for 36 h with 10 μM of carnosol analogues or DMSO (Solvent; CTRL) prior to incubation with sub-lethal concentration of 100 μM H2O2 for one hour. Western blot analysis of phosphorylated γH2AX protein level.

Carnosol purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2025 Sep:190:118397. [Abstract]

Carnosol (CO, 48 h at 10 μM). Differentiated myoblasts were treated or not (CTRL; 0.1 % DMSO) with CO, ROS, ISOR, DCO and DISOR, at a concentration of 10 μM. Two days later, myotubes were processed for indirect immunofluorescence analysis with an antibody against troponin T (green). Nuclei were visualized by DAPI staining (blue). Representative images.

Carnosol purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2025 Sep:190:118397. [Abstract]

Carnosol (CO, 48 h at 10 μM). In parallel, myotube protein extracts were analyzed by western blotting with anti-Muscle Ring-Finger Protein-1 (MuRF1; TRIM 63) antibody (green). Revert® total protein stain was used as internal loading control (red).
PLoS Biol

A high-throughput behavioral screening platform for measuring chemotaxis by C. elegans. [Abstract]

2024 Jun 27;22(6):e3002672. PMID: 38935621
Phytother Res

Carnosol inhibits KGN cells oxidative stress and apoptosis and attenuates polycystic ovary syndrome phenotypes in mice through Keap1-mediated Nrf2/HO-1 activation. [Abstract]

2023 Apr;37(4):1405-1421. PMID: 36786429
J Zhejiang Univ Sci B

Heme oxygenase 1 linked to inactivation of subchondral osteoclasts in osteoarthritis. [Abstract]

2024 Jun 15;25(6):513-528. PMID: 38910496
Int Immunopharmacol

Psoralidin, a major component of Psoraleae Fructus, induces inflammasome activation and idiosyncratic liver injury. [Abstract]

2021 Mar:92:107352. PMID: 33422760
J Supercrit Fluids

2024 Oct.
Front Cell Dev Biol

Enhancing antioxidant capacity via NRF2 pathway activation to mitigate heat stress-induced oxidative damage in bovine granulosa cells, oocytes, and embryos. [Abstract]

2026 Feb 12:14:1777760. PMID: 41769002
Drug Dev Res

Carnosol alleviates sevoflurane-induced cognitive dysfunction by mediating NF-κB pathway in aged rats. [Abstract]

2022 Sep;83(6):1342-1350. PMID: 35781309
Sci Rep

Cellular mechanisms mediating the anti-cancer effects of carnosol on gingiva carcinoma. [Abstract]

2024 May 28;14(1):12266. PMID: 38806527
Arch Pharm (Weinheim)

Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer models. [Abstract]

2022 May;355(5):e2100467. PMID: 35128717
Hum Mol Genet

Carnosol, a diterpene present in rosemary, increases ELP1 levels in familial Dysautonomia (FD) patient-derived cells and healthy adults: a possible therapy for FD. [Abstract]

2022 Oct 10;31(20):3521-3538. PMID: 35708500
Processes (Basel)

2025 Feb 25.
Biomed Res Int

Carnosol Alleviates Collagen-Induced Arthritis by Inhibiting Th17-Mediated Immunity and Favoring Suppressive Activity of Regulatory T Cells. [Abstract]

2023 Jun 28:2023:1179973. PMID: 37415927
bioRxiv

An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]

2024 Apr 3:2023.06.02.542933. PMID: 37333363

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (151.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0265 mL

15.1323 mL

30.2645 mL

5 mM

0.6053 mL

3.0265 mL

6.0529 mL

10 mM

0.3026 mL

1.5132 mL

3.0265 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Animal Administration^[1]

Mice^[1]
Mice are orally administrated Carnosol at 100 mg/kg or vehicle 5 times a week over a period of 31 days^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wang L, et al. Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2. Oncotarget. 2018 Feb 6;9(76):34200-34212. [Content Brief]

[2]. Li X, et al. Carnosol as a Nrf2 Activator Improves Endothelial Barrier Function Through Antioxidative Mechanisms. Int J Mol Sci. 2019;20(4):880. Published 2019 Feb 18. [Content Brief]

[3]. Martin D, et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem. 2004;279(10):8919-8929. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0265 mL	15.1323 mL	30.2645 mL	75.6613 mL
	5 mM	0.6053 mL	3.0265 mL	6.0529 mL	15.1323 mL
	10 mM	0.3026 mL	1.5132 mL	3.0265 mL	7.5661 mL
	15 mM	0.2018 mL	1.0088 mL	2.0176 mL	5.0441 mL
	20 mM	0.1513 mL	0.7566 mL	1.5132 mL	3.7831 mL
	25 mM	0.1211 mL	0.6053 mL	1.2106 mL	3.0265 mL
	30 mM	0.1009 mL	0.5044 mL	1.0088 mL	2.5220 mL
	40 mM	0.0757 mL	0.3783 mL	0.7566 mL	1.8915 mL
	50 mM	0.0605 mL	0.3026 mL	0.6053 mL	1.5132 mL
	60 mM	0.0504 mL	0.2522 mL	0.5044 mL	1.2610 mL
	80 mM	0.0378 mL	0.1892 mL	0.3783 mL	0.9458 mL
	100 mM	0.0303 mL	0.1513 mL	0.3026 mL	0.7566 mL

Keywords

Carnosol

17 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Carnosol

Natural Product Library Plus

Publications Citing Use of MedChemExpress (MCE) Carnosol

Alle Ribosomal S6 Kinase (RSK) Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (17)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Carnosol

Natural Product Library Plus

Publications Citing Use of MedChemExpress (MCE) Carnosol

Alle Ribosomal S6 Kinase (RSK) Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (17)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Carnosol Related Classifications

HY-N0643 Related Classifications